ABSTRACT
Tokyo Electric Power Company announced to discharge the contaminated radioactive water resulting from the Fukushima nuclear accident into the ocean after purification from 2023. Concerns remain about safety and removal efficiency of radionuclides. This study calculated the total radioactivity and simulated the marine transport of 137Cs, 90Sr, and tritium. It assessed activity concentration in ocean and marine products, lifetime doses from marine product consumption, and associated cancer risks. We found the radionuclides would be globally distributed and penetrate into deep ocean, with the highest concentrations along Japan’s eastern coast. If 137Cs and 90Sr were not removed, related cancer risks would range between 8.64 – 33.35 cases per 100,000 people, depending on age and discharge scenario. Risks would be below one case per 100,000 if only tritium is present. Efficient removal of radionuclides is crucial to mitigating health risks. This study provides evidence of potential health risks and recommendations for prevention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Vanke School of Public Health, Tsinghua University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Co-first authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
